Last updated on February 2020

HDR Brachytherapy 68-Ga-RM2 PET 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer


Brief description of study

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)

Detailed Study Description

Primary Objective:

  1. To demonstrate that 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can detect additional cancers over mpMRI.
  2. To demonstrate that 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can assess changes in response to treatment and predict progression free survival (PFS) at 24 months.

Clinical Study Identifier: NCT04264208

Find a site near you

Start Over

Stanford Cancer Center

Stanford, CA United States
  Connect »